Hong Kong-listed Zylox-Tonbridge has agreed to acquire German medical technology company Optimed. The acquisition will be done in multiple steps, with Zylox-Tonbridge having the option to purchase the entire shareholding. Optimed specializes in minimally invasive therapies and has been operating for nearly 30 years, with a presence in over 70 countries.

Optimed offers a range of products in the peripheral venous stenting segment, with clinical evidence from trials like sinus-Venous and STEVECO showing improvements in quality of life and clinical severity. Zylox-Tonbridge’s acquisition of Optimed aims to accelerate global expansion by leveraging both companies’ resources and sales networks.

The partnership is expected to create operational synergies through expanded manufacturing in Germany, ensuring a reliable supply of medical solutions for European and global markets. After the transaction, Zylox-Tonbridge will merge sales, marketing, and customer service teams to establish a unified global commercial organization. Rüdiger Hausherr will continue as CEO of Optimed under Zylox-Tonbridge’s leadership.

Dr. Jonathon Zhong Zhao, chairman and CEO of Zylox-Tonbridge, expressed excitement about the acquisition and the opportunities it presents for global expansion. The merger of the two companies will allow for a broader platform and the development of high-quality, innovative, and affordable medical solutions for patients and physicians worldwide.

Read more at Yahoo Finance: Zylox-Tonbridge to acquire German medical technology company Optimed